1. Home
  2. Live Updates
  3. Phase 3 GLOW: first-line ibrutinib plus venetoclax improves

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Georgia , United States , United Kingdom , Atlanta , American , Talha Munir Leeds , Obinutuzumab Clb , American Society Of Hematology , American Society Of Hematology Annual Meeting , American Society , Talha Munir , Leeds Teaching Hospitals , Prospective Data , Minimal Residual Disease , Fixed Duration Ibrutinib Plus Venetoclax , Versus Chlorambucil Plus Obinutuzumab , First Line Treatment , Unfit Patients , Hematology Annual ,